Resistance to two heterologous neurotropic oncolytic viruses, semliki forest virus and vaccinia virus, in experimental glioma

Journal of Virology

Volumn 87, Issue 4, 2013, Pages 2363-2366

  Vähä Koskela, Markus J V ^a,b   Le Boeuf, Fabrice ^a   Lemay, Chantal ^a   De Silva, Naomi ^a   Diallo, Jean Simon ^a   Cox, Julie ^a   Becker, Michelle ^a   Choi, Youngmin ^a   Ananth, Abhirami ^a   Sellers, Clara ^a   Breton, Sophie ^a   Roy, Dominic ^a   Falls, Theresa ^a   Brun, Jan ^c   Hemminki, Akseli ^b   Hinkkanen, Ari ^d   Bell, John C ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF HELSINKI   (Finland)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; ONCOLYTIC SEMLIKI FOREST ALPHAVIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; RECOMBINANT BETA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL ACTIVITY; CELL KILLING; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GLIOMA; GLIOMA CELL; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; NEUROTROPISM; NONHUMAN; ONCOLYTIC VIROTHERAPY; PICHINDE ARENAVIRUS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REFRACTORY PERIOD; SEMLIKI FOREST ALPHAVIRUS; SINGLE DRUG DOSE; TREATMENT OUTCOME; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS REPLICATION;

ANIMALS; DISEASE MODELS, ANIMAL; GLIOMA; MICE; ONCOLYTIC VIRUSES; SEMLIKI FOREST VIRUS; VACCINIA VIRUS;

EID: 84873828032     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01609-12     Document Type: Article

References (20)

1. Stupp R, Hegi M, Weller M. 2010. Neuro-oncology, a decade of temozolomide and beyond. Expert. Rev. Anticancer Ther. 10:1675-1677.
2. Guo ZS, Thorne SH, Bartlett DL. 2008. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785:217-231.
3. Heikkilä JE, Vähä-Koskela MJ, Ruotsalainen JJ, Martikainen MW, Stanford MM, McCart JA, Bell JC, Hinkkanen AE. 2010. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One 5:e8603. doi:10.1371/journal.pone.0008603.
4. Mättä AM, Liimatainen T, Wahlfors T, Wirth T, Vähä-Koskela M, Jansson L, Valonen P, Hakkinen K, Rautsi O, Pellinen R, Mäkinen K, Hakumäki J, Hinkkanen A, Wahlfors J. 2007. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int. J. Cancer 121:863-870.
5. Ruotsalainen J, Martikainen M, Niittykoski M, Huhtala T, Aaltonen T, Heikkilä J, Bell J, Vähä-Koskela M, Hinkkanen A. 2012. Interferon-beta sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models. Mol. Ther. 20:1529-1539.
6. Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC. 2010. Synergistic interaction between oncolytic viruses augments tumor killing. Mol. Ther. 18:888-895.
7. Le Boeuf F, Bell JC. 2010. United virus: the oncolytic tag-team against cancer! Cytokine Growth Factor Rev. 21:205-211.
8. Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA. 2009. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin. Cancer Res. 15:2777-2788.
9. Welsh RM, Che JW, Brehm MA, Selin LK. 2010. Heterologous immunity between viruses. Immunol. Rev. 235:244-266.
10. Zuniga EI, Liou LY, Mack L, Mendoza M, Oldstone MB. 2008. Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections. Cell Host Microbe 4:374-386.
11. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS. 2010. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 16:483-489.
12. Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ. 2005. Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc. Natl. Acad. Sci. U. S. A. 102:8287-8292.
13. Lamfers ML, Idema S, Bosscher L, Heukelom S, Moeniralm S, van der Meulen-Muileman IH, Overmeer RM, van d van Beusechem VVW, Gerritsen WR, Vandertop WP, Dirven CM. 2007. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin. Cancer Res. 13:7451-7458.
14. Huang PY, Guo JH, Hwang LH. 2012. Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol. Ther. 20:298-305.
15. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. 2006. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J. Virol. 80:5145-5155.
16. Naik S, Russell SJ. 2009. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert. Opin. Biol. Ther. 9:1163-1176.
17. Paglino JC, van den Pol AN. 2011. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J. Virol. 85:9346-9358.
18. Näslund TI, Uyttenhove C, Nordström EK, Colau D, Warnier G, Jondal M, Van den Eynde BJ, Liljeström P. 2007. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J. Immunol. 178:6761-6769.
19. Zhang YQ, Tsai YC, Monie A, Wu TC, Hung CF. 2010. Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol. Ther. 18:692-699.
20. Duca KA, Lam V, Keren I, Endler EE, Letchworth GJ, Novella IS, Yin J. 2001. Quantifying viral propagation in vitro: toward a method for characterization of complex phenotypes. Biotechnol. Prog. 17:1156-1165.